抗体フラグメント市場：タイプ別、抗体タイプ別、用途別-2025-2030年の世界予測

抗体フラグメント市場は、2023年に77億2,000万米ドルと評価され、2024年には80億7,000万米ドルに達すると予想され、CAGR 4.36％で成長し、2030年には104億2,000万米ドルになると予測されています。

抗体フラグメントは、バイオテクノロジーの展望の中で、フルサイズの抗体と比較して、より強化されたターゲティング能力とより少ない副作用を持つモノクローナル抗体の小さなセグメントで構成される顕著なカテゴリーを表しています。これらのフラグメントの市場は、サイズが小さいために腫瘍により効果的に浸透することができるため、標的化ドラッグデリバリーやがん治療などの治療法への応用によって牽引されています。慢性疾患の増加から、従来のモノクローナル抗体療法に代わる、より効率的で、場合によってはより安価な代替品を提供するフラグメントの必要性が高まっています。これらのフラグメントは、画像診断、感染症治療、バイオ医薬品コンジュゲートなど、多様な分野で強力な用途が見出されています。最終用途は病院、専門クリニック、新しい治療法や診断法の開発に注力する研究機関など多岐にわたる。

市場開拓の洞察により、精密医療に対する需要の急増、遺伝子工学の技術進歩、研究開発投資の増加など、成長に影響を与えるいくつかの要因が明らかになった。バイオシミラー市場の拡大や、規制当局による新規生物製剤の承認の高まりは、潜在的なビジネスチャンスです。企業は、二重特異性抗体や単一ドメインの抗体フラグメントのような革新的技術に投資することで、こうした機会を捉えることができます。しかし、市場には制約もあります。特に、研究・製造工程に関連する高コスト、知的財産権に関する課題、迅速な市場参入を妨げる可能性のある厳格な規制要件などです。

事業の成長を促進するために、業界プレーヤーはマルチターゲット治療法の開発における技術革新と、治療効果を高めるためのフラグメント半減期の改善に注力すべきです。非カノニカルアミノ酸を用いたコンジュゲーション技術の調査や新規スキャフォールドの探索は、フラグメント工学のブレークスルーにつながる可能性があります。抗体フラグメント市場の性質は非常にダイナミックで競争的であるため、新たな機会を活用しながら課題を克服するためには、強固な研究開発イニシアティブと戦略的パートナーシップの融合が必要となります。個別化医療と精密治療計画を重視することで、市場への浸透がさらに進み、持続的な成長が促進される可能性があります。

市場力学：急速に進化する抗体フラグメント市場の主要市場インサイトを公開

抗体フラグメント市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 医療診断における抗体フラグメントの使用の増加
  • 各種がんや感染症の増加
  • 創薬活動の増加
• 市場抑制要因
  • 抗体フラグメントの承認に関する厳しい規制ガイドライン
• 市場機会
  • 抗体フラグメントの臨床開発の進展
  • 高度な組換えDNA技術のイントロダクション
• 市場の課題
  • 抗がん免疫療法における不十分な有効性と副作用

ポーターのファイブフォース：抗体フラグメント市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗体フラグメント市場における外部からの影響の把握

外部マクロ環境要因は、抗体フラグメント市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗体フラグメント市場における競合情勢の把握

抗体フラグメント市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗体フラグメント市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗体フラグメント市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗体フラグメント市場における成功への道筋を描く

抗体フラグメント市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医療診断における抗体フラグメントの使用増加
    • さまざまながんや感染症の発生率の上昇
    • 創薬活動の増加
  • 抑制要因
    • 抗体フラグメントの承認に関する厳格な規制ガイドライン
  • 機会
    • 抗体フラグメントの臨床開発の進歩
    • 高度な組み換えDNA技術のイントロダクション
  • 課題
    • 抗がん免疫療法における不十分な有効性と副作用
• 市場セグメンテーション分析
  • タイプ：結合の安定性と柔軟性により、アプリケーションの観点から単一ドメイン抗体フラグメント（sdAbs）の使用が急増している
  • 抗体の種類：標的治療における高い特異性によりモノクローナル抗体の利用が拡大
  • 応用：がん治療における抗体フラグメントの応用の進化
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗体フラグメント市場：タイプ別

• F（ab）フラグメント
• F（ab'）2フラグメント
• 単一ドメイン抗体フラグメント（sdAbs）
• 単鎖可変フラグメント（scFv）

第7章 抗体フラグメント市場抗体の種類別

• モノクローナル
• ポリクローナル

第8章 抗体フラグメント市場：用途別

• がん
• 免疫不全

第9章 南北アメリカの抗体フラグメント市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の抗体フラグメント市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの抗体フラグメント市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ルピン社とアンマンファーマ社がラニビズマブの独占販売で提携
  • バーミンガム血小板グループが画期的な「ナノボディ」技術を発表
  • カリフォルニアの新興バイオテクノロジー企業アトビアは、薬物が標的に結合する方法を再考する計画を掲げて設立されました。
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Adaptimmune Therapeutics PLC
• Aenova Group GmbH
• Almac Group
• Amgen Inc.
• Antikor Biopharma
• Astellas Pharma Inc.
• Baxter International Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• Confo Therapeutics
• Dyne Therapeutics
• Eli Lilly and Company
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• Gilde Healthcare
• Johnson & Johnson Services, Inc.
• MoonLake Immunotherapeutics AG
• Novartis AG
• Numab AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB')2 FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

The Antibody Fragments Market was valued at USD 7.72 billion in 2023, expected to reach USD 8.07 billion in 2024, and is projected to grow at a CAGR of 4.36%, to USD 10.42 billion by 2030.

Antibody fragments represent a prominent category within the biotechnology landscape, consisting of smaller segments of monoclonal antibodies with enhanced targeting capabilities and fewer side effects compared to full-sized antibodies. The market for these fragments is driven by their application in therapeutic methods, such as targeted drug delivery and cancer treatment, as they can infiltrate tumors more effectively due to their smaller size. A significant necessity arises from the increasing prevalence of chronic diseases, with fragments offering more efficient and sometimes less costly alternatives to traditional monoclonal antibody therapies. These fragments find robust applications across diverse sectors, including diagnostic imaging, the treatment of infectious diseases, and as biopharmaceutical conjugates. The end-use spectrum spans hospitals, specialty clinics, and research institutes focused on developing novel cures and diagnostic methods.

Market insights reveal several factors influencing growth, such as the burgeoning demand for precision medicine, technological advancements in genetic engineering, and escalating research and development investments. Potential opportunities materialize from the expanding biosimilars market and the rising approval of novel biologics by regulatory bodies. Companies can seize these opportunities by investing in innovative technologies like bispecific antibodies and single-domain antibody fragments. However, the market also faces limitations, notably the high costs associated with research and manufacturing processes, intellectual property challenges, and stringent regulatory requirements that could hinder swift market entry.

To foster business growth, industry players should focus on innovation in developing multi-targeted therapies and improving fragment half-life to boost therapeutic efficacy. Research into non-canonical amino acids for conjugation techniques and exploring novel scaffolds can lead to breakthroughs in fragment engineering. The nature of the antibody fragment market is highly dynamic and competitive, necessitating a blend of robust R&D initiatives and strategic partnerships to navigate challenges while leveraging emerging opportunities. Emphasizing personalized medicine and precision treatment plans could further enhance market penetration and drive sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Fragments Market

The Antibody Fragments Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing use of antibody fragments in medical diagnostics
  • Rising incidences of various cancers and infectious diseases
  • Increasing number of drug discovery activities
• Market Restraints
  • Strict regulatory guidelines for the approval of antibody fragments
• Market Opportunities
  • Advancements in the clinical development of antibody fragments
  • Introduction of advanced recombinant DNA technology
• Market Challenges
  • Insufficient efficacy and adverse effects in anticancer immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Fragments Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Fragments Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Fragments Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Fragments Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Fragments Market

A detailed market share analysis in the Antibody Fragments Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Fragments Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Fragments Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibody Fragments Market

A strategic analysis of the Antibody Fragments Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs), and Single-chain Variable Fragments (scFvs).
• Based on Antibody Type, market is studied across Monoclonal and Polyclonal.
• Based on Application, market is studied across Cancer and Immunodeficiencies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing use of antibody fragments in medical diagnostics
    • 5.1.1.2. Rising incidences of various cancers and infectious diseases
    • 5.1.1.3. Increasing number of drug discovery activities
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the clinical development of antibody fragments
    • 5.1.3.2. Introduction of advanced recombinant DNA technology
  • 5.1.4. Challenges
    • 5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
  • 5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
  • 5.2.3. Application: Evolving application of antibody fragments in cancer therapy
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibody Fragments Market, by Type

• 6.1. Introduction
• 6.2. F(ab) Fragments
• 6.3. F(ab')2 Fragments
• 6.4. Single Domain Antibody Fragments (sdAbs)
• 6.5. Single-chain Variable Fragments (scFvs)

7. Antibody Fragments Market, by Antibody Type

• 7.1. Introduction
• 7.2. Monoclonal
• 7.3. Polyclonal

8. Antibody Fragments Market, by Application

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Immunodeficiencies

9. Americas Antibody Fragments Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antibody Fragments Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Fragments Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
  • 12.3.2. Birmingham Platelet Group Delivers Breakthrough 'nanobody' Technology
  • 12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adaptimmune Therapeutics PLC
• 3. Aenova Group GmbH
• 4. Almac Group
• 5. Amgen Inc.
• 6. Antikor Biopharma
• 7. Astellas Pharma Inc.
• 8. Baxter International Inc.
• 9. Biogen Inc.
• 10. Bristol-Myers Squibb Company
• 11. Confo Therapeutics
• 12. Dyne Therapeutics
• 13. Eli Lilly and Company
• 14. Evonik Industries AG
• 15. F. Hoffmann-La Roche Ltd.
• 16. Genentech, Inc.
• 17. Gilde Healthcare
• 18. Johnson & Johnson Services, Inc.
• 19. MoonLake Immunotherapeutics AG
• 20. Novartis AG
• 21. Numab AG
• 22. Pfizer Inc.
• 23. Sanofi S.A.
• 24. Takeda Pharmaceutical Company Limited
• 25. Thermo Fisher Scientific Inc.